[go: up one dir, main page]

MX2018011793A - Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. - Google Patents

Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.

Info

Publication number
MX2018011793A
MX2018011793A MX2018011793A MX2018011793A MX2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A
Authority
MX
Mexico
Prior art keywords
antigens
pharmaceutical composition
virus
antigen
hepatitis
Prior art date
Application number
MX2018011793A
Other languages
English (en)
Inventor
Cesar Aguilar Rubido Julio
Lobaina Mato Yadira
Iglesias Perez Enrique
Penton Arias Eduardo
Enrique Guillén Nieto Gerardo
Agustin Aguiar Santiago Jorge
Gonzalez Blanco Sonia
Valdes Hernandez Jorge
Vazquez Castillo Mariela
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2018011793A publication Critical patent/MX2018011793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion revela una composicion farmaceutica que comprende el antigeno de la superficie (HBsAg) del virus de la hepatitis B (VHB) y el antigeno de la nucleocapsida (o core, HBcAg) del propio virus; el HBcAg presente en dicha composicion contiene acido ribonucleico mensajero (ARNm) en una proporcion superior al 45% del total de acido ribonucleico (ARN) de dicho antigeno; debido a cambios en la constitucion de los antigenos que la componen, la composicion de la invencion es util para la prevencion o el tratamiento de la hepatitis B cronica; tambien contempla el uso de esa composicion farmaceutica en la manufactura de un medicamento para la inmunoprofilaxis o la inmunoterapia contra la infeccion por VHB, y su uso para incrementar la respuesta inmune contra un antigeno adicional que se co-administra con la mezcla de dichos antigenos.
MX2018011793A 2016-03-31 2017-03-14 Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. MX2018011793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
MX2018011793A true MX2018011793A (es) 2018-12-17

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011793A MX2018011793A (es) 2016-03-31 2017-03-14 Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.

Country Status (17)

Country Link
US (2) US11491218B2 (es)
EP (1) EP3437654B1 (es)
JP (1) JP6981992B2 (es)
KR (1) KR20180125985A (es)
CN (1) CN109219449B (es)
AR (1) AR108009A1 (es)
AU (1) AU2017243136B2 (es)
BR (1) BR112018069738A2 (es)
CU (1) CU24454B1 (es)
EA (1) EA201892212A1 (es)
ES (1) ES2965709T3 (es)
MX (1) MX2018011793A (es)
MY (1) MY202118A (es)
TW (1) TWI755383B (es)
UA (1) UA128952C2 (es)
WO (1) WO2017167317A1 (es)
ZA (1) ZA201806325B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4034158A4 (en) * 2019-09-23 2023-10-04 Ascendo Biotechnology, Inc. BIODEGRADABLE NANOCOMPLEX VACCINES, METHOD FOR SUPPRESSING HEPAPITIS B VIRUS REPLICATION AND HEPAPITIS B VIRUS SURFACE ANTIGEN SECRETION
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
JP2025506732A (ja) * 2022-02-22 2025-03-13 カロジェン コーポレイション 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞（ｖｌｖ）プラットフォーム
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN110859961A (zh) * 2013-07-26 2020-03-06 复旦大学 病毒免疫治疗药物复合物在制备治疗hbv感染药物中的应用

Also Published As

Publication number Publication date
US20200297840A1 (en) 2020-09-24
AU2017243136B2 (en) 2022-02-17
KR20180125985A (ko) 2018-11-26
AU2017243136A1 (en) 2018-10-11
WO2017167317A1 (es) 2017-10-05
ZA201806325B (en) 2020-08-26
CN109219449A (zh) 2019-01-15
TW201735945A (zh) 2017-10-16
BR112018069738A2 (pt) 2019-02-05
EP3437654B1 (en) 2023-09-20
US11491218B2 (en) 2022-11-08
JP2019510064A (ja) 2019-04-11
CA3017778A1 (en) 2017-10-05
JP6981992B2 (ja) 2021-12-17
TWI755383B (zh) 2022-02-21
EA201892212A1 (ru) 2019-03-29
HK1259329A1 (zh) 2019-11-29
AR108009A1 (es) 2018-07-04
ES2965709T3 (es) 2024-04-16
US11759517B2 (en) 2023-09-19
UA128952C2 (uk) 2024-12-11
CU20160038A7 (es) 2017-11-07
US20220193228A1 (en) 2022-06-23
EP3437654A1 (en) 2019-02-06
CU24454B1 (es) 2019-11-04
CN109219449B (zh) 2022-08-30
MY202118A (en) 2024-04-04

Similar Documents

Publication Publication Date Title
PH12019550220A1 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
MX2018011793A (es) Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
MX421406B (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
NI201700032A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
JOP20170161A1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表达沉默的组合物及方法
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
EP4483903A3 (en) Compositions and methods for enhanced innate immunity
PH12017500419A1 (en) Recoded arbovirus and vaccines
JP2019510064A5 (es)
WO2018066891A3 (ko) 인터페론 베타 변이체의 안정화 제제
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
UY31574A1 (es) Vacunas contra la malaria
RU2017138083A (ru) Применение полимиксина в качестве антидота при отравлениях аматоксинами
MX390292B (es) Vacuna heterologa atenuada viva para leptospira.